Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement signed with Empiric Logic

15 Oct 2019 07:00

RNS Number : 8397P
Open Orphan PLC
15 October 2019
 

15 October 2019

Open Orphan plc

("Open Orphan" or the "Company")

Open Orphan signs agreement with Empiric Logic

 

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement ("the Collaboration") with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan's Health Data platform, Europe's first rare disease, advocacy-led genomic database.

Empiric Logic, a leading managed software service company which provides software to the Life Sciences, Pharma, Pharma Services and Biotech sectors, will incorporate its propriety, privacy preserving, and artificial intelligence enabled software into Open Orphan's Health Data platform to aid the collection and management capabilities of the software.

The Collaboration is the final stage in the completion of Open Orphan's Genomic Health Data platform and will speed up its launch. The platform builds on the genomic analysis, database architecture know-how and prior professional experience between the founders of Empiric Logic and Maurice Treacy, Chief Commercial Officer at Open Orphan.

Cathal Friel, Chief Executive of Open Orphan commented:

"This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe."

Gareth O'Sullivan, CEO at Empiric Logic commented:

"Empiric Logic is delighted to be supporting the Open Orphan team with the final steps of preparing the Genomic Health Data platform to accept first data.

As part of the rollout of the Open Orphan database, it will be making substantial use of our artificial intelligence capabilities, such as for identification of rare-disease genetic mutations, but also for the potential identification of patients for clinical trials going forward."

Enquiries:

Open Orphan plc Tel: +353 1 644 0007Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980Tom Huddart / Billy Clegg / Dan Sherwen

 

Notes to Editors on Open Orphan:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

Notes to Editors on Empiric Logic:

Empiric Logic is a platform provider for health and genomics data analysis. This platform uses proprietary analysis software to automate key aspects of the collation, correlation and analysis of complex health and genomics data. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRMIBFTMBABBBL
Date   Source Headline
11th Mar 20217:00 amRNSJournal for Clinical Studies article publication
9th Mar 20217:00 amRNSNew contract win with Oxford BioTherapeutics
26th Feb 20214:58 pmRNSHolding(s) in Company
17th Feb 20219:00 amRNSEthics approval - COVID-19 Human Challenge Study
9th Feb 20213:57 pmRNSHolding(s) in Company
3rd Feb 20217:05 amRNSExercise of Investor Warrants & TVR
3rd Feb 20217:00 amRNSNew challenge study quarantine clinic
1st Feb 20217:00 amRNSContract extension with Carna Biosciences
21st Jan 20217:00 amRNSArticle published in Drug Discovery Today
20th Jan 20217:00 amRNSExpansion of volunteer recruitment centres
11th Jan 20217:00 amRNSFirst volunteer dosed in COVID-19 clinical trial
6th Jan 20214:29 pmRNSHolding(s) in Company
6th Jan 20217:00 amRNSContract renewal with top-3 pharmaceutical client
31st Dec 20207:00 amRNSRule 19.6(c) Confirmation
23rd Dec 20207:00 amRNSSuccessful completion of toxicology study
22nd Dec 20207:00 amRNSContract renewal with top-3 pharmaceutical client
14th Dec 20207:30 amRNSExercise of Share Options
14th Dec 20207:00 amRNSMHRA approval for nasal COVID-19 vaccine trial
7th Dec 20207:00 amRNSVenn Life Sciences contract wins
24th Nov 20207:00 amRNSDirectors Change
19th Nov 20207:00 amRNSCollaboration with HIC-VAC and Wellcome Trust
5th Nov 20207:00 amRNSNew £2.5m Influenza Challenge Study Contract Win
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:10 amRNSExercise of Share Options
30th Oct 20207:00 amRNSNew 2-year contract with a tier 1 German company
20th Oct 20207:00 amRNSContract Signed with UK Government
16th Oct 20208:47 amRNSStatement re further media comment
30th Sep 20207:00 amRNSInterim Results for 6 months ended 30 June 2020
28th Sep 20207:00 amRNSNew £4.3m Challenge Study Contract Win
24th Sep 20207:00 amRNSStatement re price movement and press speculation
23rd Sep 20204:41 pmRNSSecond Price Monitoring Extn
23rd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20207:30 amRNSExercise of Investor Warrants and Issue of Shares
22nd Sep 20207:00 amRNSNew Contract Win
7th Sep 20207:00 amRNShVIVO present at 2020 ERS International Congress
10th Aug 20207:00 amRNSMajor New Contract Win with Top 3 Pharma Company
4th Aug 20207:00 amRNSNew Contract Win with Carna Bioscience ("Carna")
28th Jul 20207:00 amRNSContract for COVID-19 Vaccine Trial
22nd Jul 202012:43 pmRNSResult of AGM
15th Jul 20207:00 amRNSOption to Acquire CHIMagents Limited
10th Jul 20208:00 amRNSEuronext Growth Dublin Notice
8th Jul 20207:00 amRNSUpcoming Investor Events
7th Jul 20207:10 amRNSExercise of Warrants
7th Jul 20207:00 amRNSAdditional Laboratory Services Contracts Signed
26th Jun 20201:05 pmRNSNotice of AGM
24th Jun 20207:00 amRNSResults for the year ended 31 December 2019
17th Jun 20209:33 amEQSHardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020
15th Jun 20207:00 amRNSPositive Phase I results published in The Lancet
12th Jun 20208:00 amRNSEuronext Growth Dublin Notice
11th Jun 202012:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.